Home » Stocks » PSNL

Personalis, Inc. (PSNL)

Stock Price: $22.75 USD 1.23 (5.72%)
Updated May 7, 2021 4:00 PM EDT - Market closed
Market Cap 998.92M
Revenue (ttm) 80.37M
Net Income (ttm) -44.55M
Shares Out 42.27M
EPS (ttm) -2.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $22.75
Previous Close $21.52
Change ($) 1.23
Change (%) 5.72%
Day's Open 22.07
Day's Range 21.72 - 23.75
Day's Volume 583,032
52-Week Range 9.69 - 53.46

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Personalis (PSNL) delivered earnings and revenue surprises of 21.62% and 2.36%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 days ago - Zacks Investment Research

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today reported financial results for the first quarter ended Mar...

2 days ago - Business Wire

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the 2021 Bank of America Healthca...

1 week ago - Business Wire

Personalis (PSNL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 week ago - Zacks Investment Research

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today it will release its first quarter 2021 financial results after the market ...

2 weeks ago - Business Wire

MENLO PARK, Calif.--(BUSINESS WIRE)-- #AACR21--Personalis Presents Data at AACR Annual Meeting 2021 Showcasing the Personalis ImmunoID NeXT Platform

4 weeks ago - Business Wire

Personalis (PSNL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

1 month ago - Zacks Investment Research

MENLO PARK, Calif.--(BUSINESS WIRE)-- #immunooncology--Personalis Announces Collaboration with MapKure to Use Personalis' NeXT Platform for Clinical Trials and Companion Diagnostic Development

1 month ago - Business Wire

MENLO PARK, Calif.--(BUSINESS WIRE)-- #PrecisionOncology--Personalis Announces Changes to its Board of Directors

1 month ago - Business Wire

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today reported financial results for the fourth quarter and full...

2 months ago - Business Wire

MENLO PARK, Calif.--(BUSINESS WIRE)--Second paragraph, first sentence of release dated February 11, 2021, should read: Interested parties may access the live call via telephone by dialing (866) 220-8061...

2 months ago - Business Wire

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the following upcoming investor c...

2 months ago - Business Wire

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today it will release its fourth quarter 2020 financial results after the market...

2 months ago - Business Wire

MENLO PARK, Calif.--(BUSINESS WIRE)-- #PrecisionOncology--Personalis Expands Leadership Team with Appointment of Susan Moriconi, VP of People and Chief Human Resources Officer

2 months ago - Business Wire

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the BTIG Virtual MedTech, Digital...

3 months ago - Business Wire

The company announced the pricing of a public offering of common stock.

3 months ago - The Motley Fool

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today announced the pricing of its previously announced underwri...

3 months ago - Business Wire

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today announced that it has commenced an underwritten public off...

3 months ago - Business Wire

A recap for my 20/20 Vision is offered for my readers. I will share my concerns about the current market conditions.

Other stocks mentioned: AMPH, AQUA, BBDC, BHVN, CFX, CRHM, GBT ...
3 months ago - Seeking Alpha

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today reported unaudited preliminary revenue for the fourth quar...

3 months ago - Business Wire

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that management will present at the 23rd Annual Needham Virtual Growth Con...

4 months ago - Business Wire

MENLO PARK, Calif.--(BUSINESS WIRE)-- #AACR20--Personalis Announces the Launch of NEOPS™, a Neoantigen-based Composite Biomarker for Cancer Immunotherapy Response

4 months ago - Business Wire

MENLO PARK, Calif.--(BUSINESS WIRE)-- #PrecisionOncology--Personalis Announces Delivery of the 100,000th Genome to the U.S. Department of Veterans Affairs Million Veteran Program

4 months ago - Business Wire

MENLO PARK, Calif.--(BUSINESS WIRE)-- #EACR--Personalis, Inc. to Present at EACR Liquid Biopsies Virtual Event

5 months ago - Business Wire

Multiple companies are working on next-gen blood biopsies tech to detect cancer. The potential market size is big according to most estimates and analysts.

Other stocks mentioned: EXAS, GH, ILMN, NTRA
5 months ago - Seeking Alpha

MENLO PARK, Calif.--(BUSINESS WIRE)-- #AMP2020--Personalis® to Present at the AMP Annual Meeting 2020

5 months ago - Business Wire

MENLO PARK, Calif.--(BUSINESS WIRE)-- #PrecisionOncology--Personalis, Inc. to Present New Data at the Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting

5 months ago - Business Wire

Personalis' (PSNL) CEO John West on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

Personalis (PSNL) delivered earnings and revenue surprises of 10.00% and 2.96%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today reported financial results for the third quarter ended Sep...

6 months ago - Business Wire

Personalis (PSNL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that company management will participate in the following upcoming investo...

6 months ago - Business Wire

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis to Announce Third Quarter 2020 Financial Results on November 5, 2020

6 months ago - Business Wire

MENLO PARK, Calif.--(BUSINESS WIRE)-- #PrecisionOncology--Personalis to Participate in Immuno Series US Virtual Meeting

6 months ago - Business Wire

MENLO PARK, Calif.--(BUSINESS WIRE)-- #PrecisionOncology--Personalis, Inc. to Present at IO Combinations 360˚

7 months ago - Business Wire

MENLO PARK, Calif.--(BUSINESS WIRE)-- #PrecisionOncology--Personalis to Participate in Digital World CB & CDx Meeting

7 months ago - Business Wire

MENLO PARK, Calif.--(BUSINESS WIRE)-- #PrecisionOncology--Personalis Receives Contract Extension and New Task Order from the VA’s Million Veteran Program – Total Awarded to Date Now $175M

7 months ago - Business Wire

MENLO PARK, Calif.--(BUSINESS WIRE)-- #PrecisionOncology--Personalis Strengthens Commercial Team with the Appointment of New Head of Population Genomics

7 months ago - Business Wire

Personalis: Deep Genomics Leader At A Good Price

8 months ago - Seeking Alpha

Personalis (PSNL) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

8 months ago - Zacks Investment Research

The company, which leans on one customer for 76% of revenue, desperately needs to diversify its customer base.

8 months ago - The Motley Fool

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis to Participate at the Needham Virtual Cancer Diagnostics 1x1 Conference

8 months ago - Business Wire

The genomics company announced a public offering of common stock.

8 months ago - The Motley Fool

MENLO PARK, Calif.--(BUSINESS WIRE)-- #PrecisionOncology--Personalis Announces Pricing of Public Offering of Common Stock

8 months ago - Business Wire

MENLO PARK, Calif.--(BUSINESS WIRE)-- #PrecisionOncology--Personalis Announces Launch of Public Offering of Common Stock

8 months ago - Business Wire

Personalis, Inc. (PSNL) CEO John West on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Personalis (PSNL) delivered earnings and revenue surprises of 14.71% and 14.34%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis Reports Second Quarter 2020 Financial Results

9 months ago - Business Wire

MENLO PARK, Calif.--(BUSINESS WIRE)-- #PrecisionOncology--Personalis, Inc.

9 months ago - Business Wire

Personalis (PSNL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

9 months ago - Zacks Investment Research

About PSNL

Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics. The company also provides a complementary liquid biopsy assay that analyzes various human genes versus. It serves biopharmaceutical customers, universities and non-profits, diagnostics companies, and government entities. The company has par... [Read more...]

Industry
Diagnostics & Research
IPO Date
Jun 20, 2019
CEO
John West
Employees
234
Stock Exchange
NASDAQ
Ticker Symbol
PSNL
Full Company Profile

Financial Performance

In 2020, Personalis's revenue was $78.65 million, an increase of 20.61% compared to the previous year's $65.21 million. Losses were -$41.28 million, 64.6% more than in 2019.

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for Personalis stock is "Buy." The 12-month stock price forecast is 37.00, which is an increase of 62.64% from the latest price.

Price Target
$37.00
(62.64% upside)
Analyst Consensus: Buy